Enigma struck the alliance with Tecan in anticipation of a fourth-quarter commercial launch of its miniaturized PCR instrument for point-of-care influenza diagnostic tests in Europe in partnership with GlaxoSmithKline.
The firms will develop tests to run on Enigma's ML platform. As part of the alliance, GSK will make an equity investment in the molecular diagnostics startup.